How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

3,019 results for

"covid 19" OR "novel coronavirus"

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

101. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD)

COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) NICE guideline Published: 9 April 2020 www.nice.org.uk/guidance/ng168 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline (...) inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: community-based care of patients with chronic obstructive pulmonary disease (COPD) (NG168) © NICE 2020. All rights reserved

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

102. COVID-19 rapid guideline: cystic fibrosis

COVID-19 rapid guideline: cystic fibrosis COVID-19 rapid guideline: cystic fibrosis NICE guideline Published: 9 April 2020 www.nice.org.uk/guidance/ng170 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals (...) and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: cystic fibrosis (NG170) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 11Contents Contents Overview 4 1 Communicating with patients and minimising risk 5 Patients not known to have

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

103. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response

COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response NICE guideline Published: 23 April 2020 www.nice.org.uk/guidance/ng172 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations (...) inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: gastrointestinal and liver conditions treated with drugs affecting the immune response (NG172) © NICE 2020. All rights reserved

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

104. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders

COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders NICE guideline Published: 3 April 2020 www.nice.org.uk/guidance/ng167 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE (...) in this guideline should be interpreted in a way that would be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: rheumatological autoimmune, inflammatory and metabolic bone disorders (NG167) © NICE 2020. All rights reserved. Subject to Notice of rights (https

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

105. COVID-19 rapid guideline: acute myocardial injury

COVID-19 rapid guideline: acute myocardial injury COVID-19 rapid guideline: acute myocardial injury NICE guideline Published: 23 April 2020 www.nice.org.uk/guidance/ng171 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: acute myocardial injury (NG171) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 11Contents Contents Overview 4 1 Communicating with patients 6 2 Minimising risk

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

106. COVID-19 rapid guideline: acute kidney injury in hospital

COVID-19 rapid guideline: acute kidney injury in hospital COVID-19 rapid guideline: acute kidney injury in hospital NICE guideline Published: 6 May 2020 www.nice.org.uk/guidance/ng175 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: acute kidney injury in hospital (NG175) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 15Contents Contents Overview 4 1 Communicating with patients 6 2 Minimising risk

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

107. COVID 19 rapid guideline: renal transplantation

COVID 19 rapid guideline: renal transplantation COVID 19 rapid guideline: renal transplantation NICE guideline Published: 19 June 2020 www.nice.org.uk/guidance/ng178 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID 19 rapid guideline: renal transplantation (NG178) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 18Contents Contents Overview 4 1 Leadership, planning and service organisation 6 2 Transplant

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

108. COVID-19 rapid guideline: interstitial lung disease

COVID-19 rapid guideline: interstitial lung disease COVID-19 rapid guideline: interstitial lung disease NICE guideline Published: 15 May 2020 www.nice.org.uk/guidance/ng177 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: interstitial lung disease (NG177) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents Overview 4 1 Communicating with patients and minimising risk 6 2

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

109. COVID-19 rapid guideline: chronic kidney disease

COVID-19 rapid guideline: chronic kidney disease COVID-19 rapid guideline: chronic kidney disease NICE guideline Published: 15 May 2020 www.nice.org.uk/guidance/ng176 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement (...) . Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: chronic kidney disease (NG176) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents Contents Overview 4 1 Communicating with patients and minimising risk 6 2

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

110. COVID-19 rapid guideline: children and young people who are immunocompromised

COVID-19 rapid guideline: children and young people who are immunocompromised COVID-19 rapid guideline: children and young people who are immunocompromised NICE guideline Published: 1 May 2020 www.nice.org.uk/guidance/ng174 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: children and young people who are immunocompromised (NG174) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 14Contents

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

111. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital

COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital NICE guideline Published: 1 May 2020 www.nice.org.uk/guidance/ng173 © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-of- rights).Your responsibility Your responsibility The recommendations in this guideline represent the view of NICE, arrived at after careful consideration (...) be inconsistent with complying with those duties. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. COVID-19 rapid guideline: antibiotics for pneumonia in adults in hospital (NG173) © NICE 2020. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and- conditions#notice-of-rights). Page 2 of 17Contents Contents

2020 National Institute for Health and Clinical Excellence - Clinical Guidelines

112. Cytokine adsorption devices for treating respiratory failure in people with COVID-19

. • Efficacy of HA330 haemoperfusion in critically ill patients with severe COVID-19 (HA- COVID19). Trials identifier: TCTR20200409006. Status: pending (not yet recruiting). Indication: COVID-19, ARDS. Devices: HA330 haemoperfusion. Date: 1 May 2021. Country: Thailand. • CytoSorb in treating critically ill hospitalized adult patients with novel coronavirus pneumonia (COVID-19). Trials identifier: ChiCTR2000030475. Status: prospective registration. Indication: novel coronavirus pneumonia (COVID-19). Devices (...) Cytokine adsorption devices for treating respiratory failure in people with COVID-19 Cytokine adsorption devices for treating respiratory failure in people with COVID-19 Medtech innovation briefing Published: 21 May 2020 www.nice.org.uk/guidance/mib217 pathways Summary Summary • The technologies technologies described in this briefing are cytokine adsorption devices. They are for reducing blood levels of cytokines in people with COVID-19 and respiratory failure. • The innovative aspects

2020 National Institute for Health and Clinical Excellence - Advice

113. Traditional Chinese medicine for treating novel coronavirus pneumonia (COVOD-19): a systematic review and meta-analysis

Traditional Chinese medicine for treating novel coronavirus pneumonia (COVOD-19): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

114. Effectiveness of integrated traditional chinese medicine (TCM) and western medicine therapies in the prevention and treatment of the 2019 novel coronavirus (2019-nCoV): a systematic review and meta-analysis

Effectiveness of integrated traditional chinese medicine (TCM) and western medicine therapies in the prevention and treatment of the 2019 novel coronavirus (2019-nCoV): a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2020 PROSPERO

115. Effect of various treatment modalities on the novel coronavirus (nCoV) infection in humans: a systematic review & meta-analysis

Effect of various treatment modalities on the novel coronavirus (nCoV) infection in humans: a systematic review & meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

116. Effect of antiviral drug therapy for improving clinical outcomes of patients with 2019 novel coronavirus infected pneumonia: a network meta-analysis

Effect of antiviral drug therapy for improving clinical outcomes of patients with 2019 novel coronavirus infected pneumonia: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

117. Antiviral drugs for novel coronavirus (2019-nCoV) pneumonia : a systematic review and network meta-analysis

Antiviral drugs for novel coronavirus (2019-nCoV) pneumonia : a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

118. Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of novel coronavirus pneumonia 2019

Efficacy and safety of chloroquine and hydroxychloroquine in the treatment of novel coronavirus pneumonia 2019 Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

119. The effects of Qing Fei Pai Du Decoction (?????) for the treatment of novel coronavirus (2019-nCoV) pneumonia : a systematic review and meta-analysis

The effects of Qing Fei Pai Du Decoction (?????) for the treatment of novel coronavirus (2019-nCoV) pneumonia : a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

120. The effects of Qing Fei Bai Du Decoction for the treatment of novel coronavirus (2019-nCoV) pneumonia : a systematic review and meta-analysis

The effects of Qing Fei Bai Du Decoction for the treatment of novel coronavirus (2019-nCoV) pneumonia : a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>